Core Viewpoint - The report outlines the independent financial advisory opinion regarding the 2025 Restricted Stock Incentive Plan of Shenzhen Meihua Chuangyi Medical Technology Co., Ltd, emphasizing the plan's compliance with relevant regulations and the necessary procedures for implementation [1][8]. Group 1: Incentive Plan Overview - The 2025 Restricted Stock Incentive Plan aims to motivate and retain key personnel by granting them restricted stocks, which will vest based on performance criteria [1][5]. - The plan includes a total of 500,000 shares to be granted, with specific vesting arrangements over a period of up to 54 months [4][5]. Group 2: Vesting Conditions - The vesting of the restricted stocks is contingent upon achieving certain performance targets related to revenue and net profit growth over the years 2025 to 2027 [6][7]. - The performance targets include a minimum revenue growth rate of 56.25% for 2025, 95.31% for 2026, and 144.14% for 2027, based on 2023 figures [6][7]. Group 3: Adjustments and Compliance - The plan has undergone adjustments, including the redistribution of shares from a departing incentive recipient to other eligible participants, ensuring compliance with the company's governance and regulatory requirements [3][4]. - The independent financial advisor confirms that both the company and the incentive recipients meet the necessary conditions for the grant of restricted stocks, with no disqualifying factors present [8][9].
美好医疗: 深圳市他山企业管理咨询有限公司关于深圳市美好创亿医疗科技股份有限公司2025年限制性股票激励计划调整及首次授予事项的独立财务顾问报告